Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 156 • 2018 ACR/ARHP Annual Meeting
Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers
Yu Zuo¹, Akrithi Udupa², Jennifer Fan¹, Una E. Makris¹, David Karp^1,3 and Yu-min Shen¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Primary thrombosis prophylaxis among asymptomatic antiphospholipid antibody (aPL) carriers is challenging. The presence of aPL does not always lead to thromboembolic events. Additional factors…
Abstract Number: 157 • 2018 ACR/ARHP Annual Meeting
Identifying Additional Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Unique Cohort of Antiphospholipid Antibody Positive Chinese Patients
Yu Zuo¹, Chun Li², Song Zhang³, Una Makris¹, David Karp⁴ and Zhan-Guo Li⁵, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Peking University People's Hospital, Beijing, China, ³University of Texas Southwestern Medical Center, dallas, TX, ⁴Rheumatology, UT Southwestern Med Ctr, Dallas, TX, ⁵Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Risk stratification of asymptomatic aPL carriers is difficult. Our objective was to identify additional clinical and epidemiological predictors of arterial thrombosis, venous thrombosis, and…
Abstract Number: 158 • 2018 ACR/ARHP Annual Meeting
Incidence and Prevalence of Antiphospholipid Syndrome in a Health Management Organization (HMO): A 15-Year Study
Aurelia Luissi¹, Marina Scolnik² and Enrique R Soriano³, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina
Background/Purpose: Antiphospholipid Syndrome (APS) is an unusual disease and there are scarce epidemiological data. Our objective was to assess incidence and prevalence rates of APS…
Abstract Number: 162 • 2018 ACR/ARHP Annual Meeting
Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/racemosa
Ecem Sevim¹, Salma Siddique², Susan Chyou³, William D. Shipman³, Ines Eugenio-Fernandez⁴, Ariel Badger⁴, Orla O`Shea⁵, Stephane Zuily⁶, Joanna Harp⁷, Cynthia Magro⁸, Oral Alpan⁹, Theresa T. Lu¹⁰ and Doruk Erkan¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Pediatric Rheumatology, Nemours Children's Health System, Wilmington, DE, ³Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ⁴O&O Alpan Medical Center, Fairfax, VA, ⁵Analytical Microscopy Core Laboratory, Hospital for Special Surgery, New York, NY, ⁶Université de Lorraine, CHRU Nancy, Nancy, France, ⁷Dermatology, Weill Cornell Medicine, New York, NY, ⁸Pathology, Weill Cornell Medicine, New York, NY, ⁹Allergy & Immunology, O&O Alpan Medical Center, Fairfax, VA, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: Endothelial proliferation is a key finding in antiphospholipid antibody (aPL)-positive patients with microthrombosis. The mTOR pathway plays a role in the endothelial proliferation leading…
Abstract Number: 168 • 2018 ACR/ARHP Annual Meeting
IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Elena Rubini³, Ana Suárez⁴, Dario Roccatello⁵, Savino Sciascia⁶ and Javier Rodríguez-Carrio⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose: Reliable biomarkers for risk stratification in Antiphospholipid Syndrome (APS) are still lacking. Anti-high-density lipoproteins antibodies (anti-HDL) showed promising results in predicting the development of…
Abstract Number: 8 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Leukocytes Demonstrate Increased Adhesive Potential: a Search for Novel Therapeutic Targets
Gautam Sule¹, William J. Kelley¹, Srilakshmi Yalavarthi¹, Alison Banka¹, Omolola Eniola-Adefeso¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Adhesion of leukocytes to the endothelium is an initiating event in the thrombosis inherent to antiphospholipid syndrome (APS). Over the years, a number of…
Abstract Number: 13 • 2017 ACR/ARHP Annual Meeting
Epidemiology of Antiphospholipid Syndrome: A Population-Based Study
Ali Duarte-Garcia¹, Michael Pham¹, Cynthia S. Crowson², Kevin Moder³, Rajiv Pruthi⁴ and Eric L. Matteson⁵, ¹Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, R, MN, ⁵Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: The epidemiology of definite antiphospholipid syndrome (APS) in the general population has not been described. A recent meta-analysis (Andreoli L, et al. Arth Care…
Abstract Number: 14 • 2017 ACR/ARHP Annual Meeting
Abnormalities in Th1, Th2 and Th17 Lymphoid Subpopulations in Long-Term Evolution Primary Antiphospholipid Syndrome
Gabriela Medina¹, Oscar I Florez-Durante², Laura Arcelia Montiel Cervantes³, Rubiraida Molina Aguilar², Elba Reyes Maldonado² and Luis J. Jara⁴, ¹Clinical Research Unit, Hospital de Especialidades Centro Medico La Raza,IMSS, Mexico City, Mexico, ²Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico, ³Hematology Laboratory, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ⁴Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico
Background/Purpose: Primary antiphospholipid antibody syndrome (PAPS) is characterized by recurrent thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). Lymphoid subpopulations and innate…
Abstract Number: 15 • 2017 ACR/ARHP Annual Meeting
Methodology and Systematic Review of the Literature for the Mcmaster RARE-Best Practice Clinical Practice Guideline on Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome
Kimberly Legault¹, Christopher Hillis¹, Cindy Yeung¹, Elie Akl², Marc Carrier³, Ricard Cervera⁴, Mark Crowther¹, Francesco Dentali⁵, Doruk Erkan⁶, Gerard Espinosa⁷, Munther A Khamashta⁸, Joerg Meerpohl⁹, Karen Moffatt¹⁰, Sarah O'Brien¹¹, Vittorio Pengo¹², Jacob Rand¹³, Ignasi Rodriguez¹⁴, Lisa Thom¹⁵, Holger Schunemann¹ and Alfonso Iorio¹, ¹McMaster University, Hamilton, ON, Canada, ²American University of Beirut, Beirut, Lebanon, ³University of Ottawa, Ottawa, ON, Canada, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Insubria University, Insubria, Italy, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁷Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁸Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ⁹University of Freiburg, Freiburg, Germany, ¹⁰Hamilton Health Sciences, Hamilton, ON, Canada, ¹¹Nationwide Children's, Columbus, OH, ¹²Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ¹³NY Presbyterian Hospital, New York, NY, ¹⁴Rheumatology, Hospital Clinica, Barcelona, Spain, ¹⁵None (patient representative), Oxford, United Kingdom
Background/Purpose: Catastrophic antiphospholipid syndrome (CAPS), a rare disease, is characterized by the rapid onset of widespread thrombosis associated with multi-organ failure in patients meeting the…
Abstract Number: 17 • 2017 ACR/ARHP Annual Meeting
Thrombotic Events in Pediatric Systemic Lupus Erythematosus: A Preliminary Analysis of a Large, Single-Center Cohort
Jennifer Rammel¹, Martha Curry² and Marietta M. de Guzman³, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ³Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: While pediatric systemic lupus erythematosus (pSLE) represents only 20% of all SLE cases, pSLE patients often have more aggressive disease with multi-organ involvement. These…
Abstract Number: 108 • 2017 ACR/ARHP Annual Meeting
Impact of Antiphospholipid Syndrome Ibook on Medical Students’ Improvement of Knowledge: An International Randomized Controlled Experimental Study
Stephane Zuily¹, Laurent Phialy², Eloïse Germain², Ozan Unlu³, Virginie Dufrost⁴, Isabelle Clerc-Urmès⁴, Jessica R. Berman⁵, Michael Lockshin⁶, Denis Wahl⁷ and Doruk Erkan⁸, ¹Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, CHRU de Nancy, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Auto-Immune Diseases; Inserm U1116; Lorraine University, Nancy, France, ²Lorraine University, Nancy School of Medicine, Nancy, France, ³Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Nancy Academic Hospital, Nancy, France, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Hospital for Special Surgery, NYC, NY, ⁷CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ⁸Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: iBooks, a free electronic book application by Apple, is well-suited for publishing interactive medical texts. To date, no iBook on Antiphospholipid Syndrome (APS) exists,…
Abstract Number: 1295 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcome in Patients with SLE Compared to Patients with Other Inflammatory Rheumatic Diseases: Real World Data from a Prospective Pregnancy Register
Rebecca Fischer-Betz¹, Christina Bungartz², Matthias Schneider¹, Jutta Richter¹, Anja Weiss², Angela Zink³ and Anja Strangfeld⁴, ¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany, ⁴Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: SLE pregnancies are complicated due to risk for maternal disease exacerbation and potential for fetal and neonatal complications. With careful pre-pregnancy counseling and monitoring…
Abstract Number: 2564 • 2017 ACR/ARHP Annual Meeting
Inhibition of Neutrophil Elastase Protects Against Glomerulonephritis and Thrombosis in a Mouse Model of Lupus
Gautam Sule¹, Levi F. Mazza¹, Nayef M. Kazzaz¹, Srilakshmi Yalavarthi¹, He Meng¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Neutrophils are potential instigators of autoimmunity and effectors of organ damage in lupus. However, there is presently no consensus as to whether inhibition of…
Abstract Number: 2759 • 2017 ACR/ARHP Annual Meeting
The Risk of Ischaemic Stroke in Primary APS Patients: A Prospective Study
Massimo Radin¹, Karen Schreiber², Irene Cecchi³, Dario Roccatello⁴, Maria Jose Cuadrado⁵ and Savino Sciascia⁶, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: The antiphospholipid syndrome(APS)is an autoimmune condition characterized by thrombosis and/or pregnancy morbidity andpersistent positivityfor antiphospholipid antibodies(aPL). The most common neurological manifestation of APS is…
Abstract Number: 2761 • 2017 ACR/ARHP Annual Meeting
Adenosine Receptor Agonism Protects Against Antiphospholipid Antibody-Mediated Netosis and Venous Thrombosis
Ramadan A. Ali¹, He Meng¹, Srilakshmi Yalavarthi¹, Yogendra Kanthi¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: We have previously reported that antiphospholipid antibodies (aPL) activate neutrophils and thereby exaggerate neutrophil extracellular trap release (NETosis), which potentially contributes to the thrombotic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].